Leishmaniasis, Autoimmune Rheumatic Disease, and Anti–Tumor Necrosis Factor Therapy, Europe

Ioannis D. Xynos, Maria G. Tektonidou, Dimitrios Pikazis, and Nikolaos V. Sipsas

We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases in Greece. To assess trends in leishmaniasis reporting in this patient population, we searched the literature for similar reports from Europe. Reports increased during 2004–2008, especially for patients treated with anti–tumor necrosis factor agents.

We report 2 new cases of leishmaniasis involving patients with autoimmune rheumatic diseases who received anti–tumor necrosis factor (anti–TNF) agents. We also reviewed all similar cases from Europe reported in the literature, and we discuss the implications of leishmaniasis in the setting of anti–TNF therapy, which is associated with increased risk for opportunistic infections (1).

The Study

Patient 1, a 55-year-old man who had received a diagnosis of ankylosing spondylitis 7 years previously, was admitted to Laikon Hospital, Athens, Greece, in May 2005 for evaluation of encrusted vesicular lesions on the face. The lesions were painless but mildly pruritic. The patient had been receiving nonsteroidal antiinflammatory agents until 12 months before admission, when his medications were changed to infliximab (3 mg/kg) plus methotrexate (10 mg weekly) because of his deteriorating clinical condition. He was living in a leishmaniasis-endemic area in Athens, had no pets in his house, and had no history of recent travel abroad. The central scale was removed from one of the lesions, and scrapings from the base of the lesion were stained with Giemsa stain, which showed intracellular amastigotes with peripheral nuclei and rod-shaped kinetoplasts. Results of indirect immunofluorescent antibody (IFA) testing were positive for Leishmania parasites (titer 6,400). Infliximab and methotrexate therapy was discontinued, and treatment with liposomal amphotericin B was started at a dose of 3 mg/kg, for days 1 to 5, and 2 additional doses (3 mg/kg) on days 14 and 21. Eighteen months later, treatment with etanercept was begun due to the patient’s severe spondyloarthritis; 2 years after the new anti–TNF treatment, he is well, with no signs or symptoms of leishmaniasis.

Patient 2, a 71-year-old woman who had giant cell arteritis, was admitted to the Euroclinic Hospital, Athens, in May 2005 with a high fever and fatigue. The patient had been treated with infliximab (0.25 mg/kg) and variable doses of methylprednisolone for the previous 2 years. Methotrexate (10 mg/week) was added 1 year before admission. She was also living in an Athens suburb, which is leishmaniasis-endemic, and had 4 dogs. Laboratory tests showed a high level of C-reactive protein (163 mg/L, reference range 0–6 mg/L), high erythrocyte sedimentation rate (77 mm/h), pancytopenia (hemoglobin level 12.5 g/dL, leukocyte count 3,300/mm³, platelet count 122,000/mm³), and diffuse hyperglobulinemia. The examination of Giemsa-stained smears from bone marrow aspirate demonstrated abundant Leishmania parasites, and IFA was marginally positive for Leishmania antibodies (titer 400). PCR was positive for the detection of the Leishmania genome in peripheral blood. Infliximab and methotrexate treatment was discontinued, and treatment with intravenous liposomal amphotericin B was started at a dose of 3 mg/kg for 5 days. Two days later, the fever subsided, and within the next few days, the patient recovered from pancytopenia, while the inflammatory markers showed a gradual decrease. She received 2 additional doses of liposomal amphotericin B (3 mg/kg) on days 7 and 14, and by that time, she exhibited no signs or symptoms of visceral leishmaniasis.

We then searched Medline, EMBASE, and Current Contents databases for all reports on leishmaniasis in Europe and the Mediterranean area among patients with autoimmune rheumatic diseases, which are often treated with anti–TNF agents. In our search strategy, we used medical subject heading terms and text words, including rheumatoid arthritis, juvenile rheumatoid arthritis, Still’s disease, seronegative arthritis, psoriatic arthritis, Behçet’s disease, ankylosing spondylitis, reactive arthritis, vasculitis, giant cell arteritis, Wegener’s granulomatosis (ANCA [anti-neutrophil cytoplasmic antibody]–associated vasculitis), panarteritis nodosa, leishmaniasis, Leishmania, and anti–TNF. We searched the reference list of each resulting report for additional publications. We used no language or time restrictions.

All retrieved articles were case reports. We found 13 additional cases of leishmaniasis in patients with autoimmune rheumatic diseases (2–14), all published after the introduction of anti–TNF agents in 1998 (Table). All 15 patients (including our 2 patients) were treated in the past or at the time of the diagnosis of leishmaniasis with ≥1...
standard immunosuppressive agents, including corticosteroids (11/14 [78.5%]) patients for whom treatment details were reported), methotrexate (9/14 [64.3%]), cyclosporine (3/14 [21.4%]), cyclophosphamide (3/14 [21.4%]), azathioprine (2/14 [14.3]), and chlorambucil (1/14 [7.1%]). Seven (46.6%) patients received an anti-TNF agent along with standard immunosuppressive agents. Two of the 15 reported patients had been treated with a recombinant interleukin–1 receptor antagonist (anakinra; Amgen Inc., Thousand Oaks, CA, USA) (5,13). In most of the patients, visceral leishmaniasis developed (13 patients, 86.6%), while cutaneous leishmaniasis developed in 2 patients (1 was receiving an anti-TNF agent). All patients were living in leishmaniasis-endemic areas of Europe (Figure).

The anti-TNF agents were introduced into clinical practice in 1998, and the first case of leishmaniasis associated with anti-TNF blockade occurred in 2001 (4). During the 6-year period (1998–2003), a total of 6 reports were made of leishmaniasis in patients with rheumatic diseases; 1 (16.6%) occurred in a patient treated with an anti-TNF agent. During the ensuing 5 years (2004–2008), 9 cases of leishmaniasis were reported, 6 (66.6%) in patients receiving anti-TNF agents.

The median duration of previous immunosuppressive therapy, before the diagnosis of leishmaniasis, was 60 months (range 2–360 months) for all 15 patients (Table). For the 7 patients who received anti-TNF agents, the median duration of anti-TNF treatment was 18 months (range 2–360 months). Six of these 7 patients were receiving anti-TNF agents when symptoms and signs of leishmaniasis occurred. In 1 patient (5), biologic treatments had been discontinued 6 months before the diagnosis of leishmaniasis (Table). Only 1 patient had been tested for antibodies against Leishmania spp. before immunosuppressive therapy was begun, and the results were negative (6). Therefore, this is the only case with compelling evidence that leishmaniasis was a primary infection and not reactivation of a latent infection.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Country</th>
<th>Age, y/sex</th>
<th>Disease</th>
<th>Anti-TNF treatment</th>
<th>Other immunosuppressive treatments</th>
<th>Form of Leishmania infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>France</td>
<td>66/M</td>
<td>ANCA-associated vasculitis</td>
<td>NA NA</td>
<td>Cyclophosphamide, methotrexate, corticosteroids</td>
<td>120 Visceral (7)</td>
</tr>
<tr>
<td>2</td>
<td>Israel</td>
<td>56/M</td>
<td>Rheumatoid arthritis</td>
<td>NA NA</td>
<td>Methotrexate, corticosteroids</td>
<td>120 Cutaneous (8)</td>
</tr>
<tr>
<td>3</td>
<td>Italy</td>
<td>35/M</td>
<td>Behçet disease</td>
<td>NA NA</td>
<td>Chlorambucil, corticosteroids</td>
<td>36 Visceral (9)</td>
</tr>
<tr>
<td>4</td>
<td>Spain</td>
<td>50/M</td>
<td>Rheumatoid arthritis</td>
<td>NA NA</td>
<td>Methotrexate, corticosteroids</td>
<td>120 Visceral (10)</td>
</tr>
<tr>
<td>5</td>
<td>Italy</td>
<td>60/M</td>
<td>Polyarteritis nodosa</td>
<td>NA NA</td>
<td>Cyclophosphamide, corticosteroids</td>
<td>2 Visceral (11)</td>
</tr>
<tr>
<td>6</td>
<td>Spain</td>
<td>55/M</td>
<td>Psoriatic arthritis</td>
<td>Infliximab 9</td>
<td>No details given</td>
<td>300 Visceral (2)</td>
</tr>
<tr>
<td>7</td>
<td>Italy</td>
<td>76/M</td>
<td>ANCA-associated vasculitis</td>
<td>NA NA</td>
<td>Cyclophosphamide, corticosteroids</td>
<td>36 Visceral (12)</td>
</tr>
<tr>
<td>8</td>
<td>France</td>
<td>53/F</td>
<td>Rheumatoid arthritis</td>
<td>Infliximab 12</td>
<td>Azathioprine, corticosteroids</td>
<td>12 Visceral (3)</td>
</tr>
<tr>
<td>9</td>
<td>Italy</td>
<td>69/F</td>
<td>Rheumatoid arthritis</td>
<td>Adalimumab 25</td>
<td>Methotrexate, corticosteroids</td>
<td>360 Visceral (4)</td>
</tr>
<tr>
<td>10</td>
<td>Greece</td>
<td>60/F</td>
<td>Rheumatoid arthritis</td>
<td>Etanercept 18†</td>
<td>Cyclophosphamide, corticosteroids, anakinra</td>
<td>96 Visceral (5)</td>
</tr>
<tr>
<td>11</td>
<td>France</td>
<td>9/F</td>
<td>Juvenile rheumatoid arthritis</td>
<td>NA NA</td>
<td>Cyclophosphamide, corticosteroids, anakinra</td>
<td>60 Visceral (13)</td>
</tr>
<tr>
<td>12</td>
<td>Greece</td>
<td>45/M</td>
<td>Psoriatic arthritis</td>
<td>Infliximab 60</td>
<td>Methotrexate, corticosteroids</td>
<td>60 Visceral (6)</td>
</tr>
<tr>
<td>13</td>
<td>Greece</td>
<td>65/F</td>
<td>Rheumatoid arthritis</td>
<td>NA NA</td>
<td>Methotrexate</td>
<td>96 Visceral (14)</td>
</tr>
<tr>
<td>14</td>
<td>Greece</td>
<td>71/F</td>
<td>Giant cell arteritis</td>
<td>Infliximab 24</td>
<td>Methotrexate, corticosteroids</td>
<td>24 Visceral This study</td>
</tr>
<tr>
<td>15</td>
<td>Greece</td>
<td>55/M</td>
<td>Ankylosing spondylitis</td>
<td>Infliximab 12</td>
<td>Methotrexate</td>
<td>12 Cutaneous This study</td>
</tr>
</tbody>
</table>

*TNF, tumor necrosis factor; Ref., reference; ANCA, anti-neutrophil cytoplasmic antibody; NA, not applicable.
†All biologic treatments had been terminated 6 mo before leishmaniasis occurred.
Due to underreporting, the reported cases may underesti-

mate the real incidence of leishmaniasis among patients with autoimmune rheumatic diseases.

Prospective studies to estimate the incidence of the disease, the impact of risk factors and the need for sero-
logic screening for leishmaniasis before initiation of anti-
TNF agents or any other immunosuppressive treatment are clearly needed. This is particularly important since currently only a few patients with autoimmune rheumatic diseases receive anti-TNF agents (15). Therefore, the use of anti-TNF treatment is likely going to increase, possibly causing a parallel increase in opportunistic infections such as leishmaniasis.

N.V.S. received support from the Special Account for Research Funds of the National and Kapodistrian University of Athens, Greece.

Dr Xynos is a senior resident in General Internal Medicine at Laikon General Hospital in Athens, Greece, and is affiliated with the Infectious Diseases Unit, Department of Pathophysiology, University of Athens Medical School. His research interests include the study of infections in patients with autoimmune rheumatic diseases.

References

1. Winthrop KL. Risk and prevention of tuberculosis and other seri-
oun opportunistic infections associated with tumor necrosis fac-
2. Romani-Costa V, Sanchez C, Moya F, Estany C. Visceral leish-
maniasis related to infliximab administration. Enferm Infecc Microbiol 
3. Fabre S, Gibert C, Lecichie C, Demeure J, Jorgesen C, Sany J. Vis-
ceral leishmaniasis infection in a rheumatoid arthritis patient treated 
C. Visceral leishmaniasis infection in a rheumatoid arthritis patient 
treated with adalimumab. Rheumatology. 2006;45:1446–8. DOI: 
10.1093/rheumatology/ke1235
5. Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leish-
maniasis infection in a patient with rheumatoid arthritis treated 
s10067-006-0356-5
6. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient 
with psoriatic arthritis treated with infliximab: reactivation of a 
s10067-007-0775-y
uto JP. Visceral leishmaniasis associated with Wegener disease. 
Use of lipid complex amphotericin B and liposomal amphotericin B. 
8. Vardy DA, Cohen A, Kachko L, Zvulunov A, Frankenburg S. Re-
lapse of cutaneous leishmaniasis in a patient with an infected subcu-
F. A case of Behcet’s disease complicated by visceral leishman-
iasis and myelodysplasia: clinical considerations. Haematologica. 


Address for correspondence: Nikolaos V. Sipsas, Pathophysiology Department, Athens University Medical School, Mikras Asias 75, Athens, 11527, Greece; email: nsipsas@med.uoa.gr